Volume 10, Number 7—July 2004
Family Cluster of Mayaro Fever, Venezuela
A cluster of protracted migratory polyarthritis involving four adult family members occurred in January 2000 after a brief overnight outing in a rural area of Venezuela. Laboratory testing demonstrated Mayaro virus as the cause of the cluster. These results documented the first human cases of Mayaro virus in Venezuela.
Mayaro virus (MAYV), the cause of Mayaro fever, is a member of the genus Alphavirus, family Togaviridae, and is closely related to Chikungunya, O’nyong-nyong, Ross River, Barmah Forest, and Sindbis viruses (1–3). Infection by these viruses produce similar clinical illnesses in humans (4–8). Mayaro fever is typically a denguelike acute febrile illness 3–5 days in duration, characterized by headache, retroorbital pain, arthralgias, arthritis, myalgias, vomiting, diarrhea, and rash (8). However, joint involvement in Mayaro fever may persist for several months and in some cases precede the fever. Moderate-to-severe polyarthritis, occasionally incapacitating, is a prominent feature of the disease (8).
MAYV is enzootic in South America, where the suspected vectors are forest-dwelling Haemagogus mosquitoes, and the vertebrate hosts are marmosets and other nonhuman primates (8). Most human cases occur sporadically and involve persons who work or reside in humid tropical forests (8,9). Nevertheless, several small outbreaks of Mayaro fever have been described in residents of rural communities of the Amazon region of Brazil, Bolivia, and Peru (8–10). Airborne transmission has been reported among laboratory personnel (11). Although MAYV is enzootic in several South American countries, this report describes the first human cases of Mayaro fever in Venezuela. The cases occurred among members of the same family after a single day’s exposure to a semirural forested area. The observations we report were made in response to the Ministry of Health’s request to determine the cause of the cluster of cases.
Clinical cases resembling dengue fever were studied in the vicinity of Padrón Agriculture Station, in Miranda State, north-central Venezuela (10°13′22″ N; 66°17′56″ W; 50 m elevation), a location where entomologic and epidemiologic studies on Venezuelan equine encephalitis virus (VEEV) and other arboviruses were conducted from 1997 to 1998 (12). This area, originally covered by lowland tropical rain forest, was converted into cacao (Theobroma cacao) plantations. Indigenous tall trees (Erythrina poeppigiana, Ceiba pentandra, Ficus sp., Hura crepitans, Bauhinia sp.), were preserved so that the area resembled a natural forest habitat. The mean temperature and annual rainfall were 27.2°C and 2,324 mm, respectively, with the rainy season normally lasting from May to December.
Four adult members of the same family (age range 26–58 years), spent a single night together in early January 2000 near the Padrón Agriculture Station. While sharing an outdoor dinner, they were frequently bitten by mosquitoes. Three days later, all four had a sudden onset of malaise, fever (up to 40°C), retroocular pain, generalized headache, conjunctival suffusion, flushing of the face and neck, myalgias, and severe incapacitating polyarthralgias and polyarthritis which mainly involved the small joints of the hands, wrists, ankles, and toes. Joints became swollen and tender, but effusion was not evident. Pain was intense and worsened with motion. Limbs felt weak and very sensitive to touch. Joint stiffness in the morning and after inactivity was a prominent complaint. On day 5 of illness, a rapidly spreading maculopapular rash developed, which involved neck, trunk, and limbs. The rash persisted for 2 days, followed by desquamation. In three of the patients, painful cervical, preauricular, and retroauricular lymphadenopathies occurred and lasted approximately 2 weeks. Beyond week 2 of illness, only severe joint symptoms and lower limb hyperesthesias persisted, but they steadily resolved during a 6-month period. Clinical laboratory results were unremarkable except for a transient and mild increase in erythrocyte sedimentation rate and serum levels of alanine aminotransferase, and a moderate lymphocytosis.
Serum samples were obtained 3 months after onset of symptoms, when the patients were first seen at consultation by one of the authors. Samples were also collected an additional 3 months after the initial samples were collected. The patients’ initial signs and symptoms resembled a classical febrile syndrome, and the patients had a history of suspected risk for arboviral infection. Therefore, all samples were tested initially at a 1:100 dilution for immunoglobulin (Ig) M antibodies to MAYV; VEEV; dengue viruses (DENV) 1, 2, 3, and 4; yellow fever virus (YFV); and Oropouche virus (OROV) by using an IgM antibody-capture enzyme-linked immunosorbent assay (MACEIA) (9,12). Reactive samples were subsequently retested for IgM antibody at serial dilutions ranging from 1:200 through 1:102,400 to determine end-point titers. Serum samples were also tested by an indirect ELISA for IgG antibodies to the above-mentioned viruses (9,13). A patient with MAYV disease was defined as a person with compatible clinical illness, for whom IgM antibody titers to MAYV and VEEV were >400 and <100, respectively.
Serologic results indicated that three of the four family members had a MAYV viral infection. Assay of serum samples obtained 3 months after onset of symptoms from the three members showed high specific Mayaro viral IgM antibody ranging from 3,200 to 6,400 and IgG antibody titers ranging from 6,400 to 12,800 (Table). Testing of samples from the fourth patient were positive for MAYV IgG antibody only. Subsequent samples taken approximately 3 months later were IgM negative but remained positive for MAYV IgG antibody. All patients were negative for VEEV IgM antibody but had VEEV IgG antibody ranging from 100 to 800. Assay results for DENV and OROV IgM and IgG were negative. Simlarly, the patients were negative for YFV IgM antibody but had IgG antibody to this virus.
MAYV has not been isolated in Venezuela, but isolates have been obtained from humans, wild vertebrates, and mosquitoes in Colombia, Brazil, Suriname, Guyana, French Guiana, Peru, United States, and Bolivia (2,8–10,14–17). In addition, serologic survey data suggest that MAYV infection is relatively common among humans in rural populations of northern South America and the Amazon River basin (2,8,9,14–16). This virus is believed to be maintained in a sylvan cycle involving wild vertebrates, such as nonhuman primates and possibly birds, and Haemagogus mosquitoes (2,8,18). Three species of that genus, H. celeste, H. equinus, and H. lucifer, have recently been identified in the area where the Venezuela patients acquired MAYV infection (12). Also, the red howler monkey (Alouatta seniculus), a suspected host of MAYV in nature, is common in the area. Thus, the results of this study suggest that these first documented cases of Mayaro fever in Venezuela were acquired during an overnight outing in a rural area where MAYV may have been circulating in a cycle involving Haemagogus mosquitoes and red howler monkeys.
Of note, convalescent-phase serum samples from an additional unrelated patient (a 40-year-old woman who lived in a nearby rural location), obtained approximately 4 months after she had recovered from a self-limited febrile illness with polyarthritis similar to that described in the patients involved in this report, showed high (25,600) MAYV IgG antibody titers. These samples were negative for IgM antibody, however, which provides further evidence that MAYV was enzootic in the area.
As observed in this study, Mayaro fever cases are usually sporadic and occur in persons with a history of recent activities in humid tropical forests (4,8,9,19). Typically, Mayaro fever ensues approximately 1 week after infection (4,8). However, shorter incubation periods, similar to those observed in these Venezuelan cases, are occasionally observed. Members of the family described in this outbreak had symptoms and clinical courses consistent with previously documented MAYV patients. Abrupt onset of fever, frontal headaches, myalgias, and incapacitating arthralgias were predominant complaints. A maculopapular rash, also a common manifestation in up to 90% of children and 50% of adults (4,8,9,18), was prominent in these patients, lasting 2 days and followed by desquamation. Up to one third of patients initially have nausea, vomiting, and diarrhea (4,8,9,18,19), but these symptoms were not experienced in this family.
Little information is available on the kinetics of MAYV IgM antibodies for Mayaro fever patients during long-term follow-up examinations. While obtaining acute-phase blood samples from the patients in this study was bit possible, existing data indicate that detectable IgM antibody develops after viremia subsides, which is usually 4–5 days after the onset of symptoms (9,19). Our data indicated that IgM antibody persisted for >3 but <6 months for our patients. These are the first documented data on the persistence of IgM antibody following a Mayaro viral infection and will be useful for interpreting diagnostic test results. To our knowledge, this is the first report of human cases of MAYF in Venezuela and, therefore, further documents the public health importance of this disease.
Dr. Torres is a tropical medicine professor at the Universidad Central de Venezuela in Caracas. He is head of the Infectious Diseases Section of the Tropical Medicine Institute. Internal medicine, infectious diseases, and tropical medicine are his specialties. Primary research interests include epidemiology and pathogenesis of tropical endemic infections.
We thank the Virology Laboratory at the U.S. Naval Medical Research Center, Lima, Peru, under the guidance of Carolina Guevara, for processing human specimens, and Eduardo Gotuzzo for his support of this study.
This work was supported by Work Unit Number (WUN) No. 847705 82000 25GB B0016 GEIS-LIMA. The opinions and assertions contained herein are those of the authors and are not to be construed as official or reflecting the views of the Department of the Navy or the Naval service at large.
- Karabatsos N. Antigenic relationships of group A arboviruses by plaque reduction neutralization test. Am J Trop Med Hyg. 1975;24:527–32.
- Karabatsos N, ed. International catalogue of arboviruses including certain other viruses of vertebrates. 3rd ed. San Antonio (TX): American Society Tropical Medicine and Hygiene; 1985. p. 673–4.
- Calisher CH, Karabatsos N. Arbovirus serogroups: definition and geographic distribution. In: Monath TP, editor. The arboviruses: epidemiology and ecology. Vol. 1. Boca Raton (FL): CRC Press; 1988. p. 19–57.
- Tesh RB. Arthritides caused by mosquito-borne viruses. Annu Rev Med. 1982;33:31–40.
- Phillips DA, Murray JR, Aaskov JG, Wiemers MA. Clinical and subclinical Barmah Forest virus infection in Queensland. Med J Aust. 1990;152:463–6.
- Espmark A, Niklasson B. Okelbo disease in Sweden: epidemiological, clinical, and virological data from the 1982 outbreak. Am J Trop Med Hyg. 1984;33:1203–11.
- Anderson CR, Downs WG, Wattley GH, Ahin NW, Reese AA. Mayaro virus: a new human disease agent. Isolation from blood of patients in Trinidad, B.W.I. Am J Trop Med Hyg. 1957;6:1012–6.
- Pinheiro FP, LeDuc JW. Mayaro virus disease. In: Monath TP, editor. The arboviruses: epidemiology and ecology. Vol. 3. Boca Raton (FL): CRC Press; 1998. p. 137–50.
- Tesh RB, Watts DM, Russell KL, Karabatsos N, Damodaram C, Cabezas C, Mayaro virus disease: an emerging mosquito-borne zoonosis in tropical South America. Clin Infect Dis. 1999;28:67–73.
- Watts DM. Mayaro fever. In: Strickland GT, editor. Hunter’s tropical medicine and emerging infectious diseases. 8th ed. Philadelphia (PA): W.B. Saunders Co.; 2000. p. 251–2.
- Junt T, Heraud JM, Lelarge J, Labeau B, Talarmin A. Determination of natural versus laboratory human infection with Mayaro virus by molecular analysis. Epidemiol Infect. 1999;123:511–3.
- Salas RA, Garcia CZ, Liria J, Barrera R, Navarro JC, Medina G, Ecological studies of enzootic Venezuelan equine encephalitis in north-central Venezuela, 1997–1998. Am J Trop Med Hyg. 2001;64:84–92.
- Watts DM, Lavera W, Callahan J, Rossi C, Oberste MS, Roehrig JT, Venezuelan equine encephalitis and Oropouche virus infections among Peruvian army troops in the Amazon region of Peru. Am J Trop Med Hyg. 1997;56:661–7.
- Metselaar D. Isolation of arboviruses of group A and group C in Suriname. Trop Geogr Med. 1966;18:137–42.
- Talarmin A, Chandler LJ, Kazanji M, De Thoisy B, Debon P, Lelarge J, Mayaro virus fever in French Guiana: isolation, identification and seroprevalence. Am J Trop Med Hyg. 1998;59:452–6.
- Black FL, Hierholzer WJ, Pinheiro FP, Evans AS, Woodall JP, Opton EM, Evidence for persistence of infectious agents in isolated human populations. Am J Epidemiol. 1974;100:230–50.
- Calisher CH, Gutierrez E, Maness KS, Lord RD. Isolation of Mayaro virus from a migrating bird captured in Louisiana in 1967. Bull Pan Am Health Organ. 1974;8:243–8.
- Hoch AL, Peterson NE, LeDuc JW, Pinheiro FP. An outbreak of Mayaro virus disease in Belterra, Brazil. Entomological and ecological studies. Am J Trop Med Hyg. 1981;30:689–98.
- Piheiro FP, Freitas RB, Travossos da Rosa JR, Gabbay YB, Mello WA, LeDuc JW. An outbreak of Mayaro virus disease in Belterra, Brazil. 1. Clinical and virological findings. Am J Trop Med Hyg. 1981;30:674–81.
- Table. Mayaro and Venezuelan equine encephalitis viral IgM and IgG antibodies demonstrated by an antibody-capture ELISA in serum samples obtained from three Venezuelan family membersa
Suggested citation for this article: Torres JR, Russell KL, Vasquez C, Tesh RB, Salas R, Watts DM. Family clustser of Mayaro fever, Venezuela. Emerg Infect Dis [serial on the Internet]. 2004 Jul [date cited]. Available from: http://wwwnc.cdc.gov/eid/article/10/7/03-0860
Please use the form below to submit correspondence to the authors or contact them at the following address:
Jaime R. Torres, Instituto de Medicina Tropical, UCV, Apartado 47019, Caracas 1041-A, Venezuela, fax: +58-212-987-6590
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: January 27, 2011
- Page last updated: January 27, 2011
- Page last reviewed: January 27, 2011
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)